RANK-L Binding Peptides for Bone Resorption Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone disorders like osteoporosis, particularly those targeting RANK-L mediated bone resorption, face challenges such as short duration of action, high production costs, and accessibility issues due to the size of full-size antibodies, necessitating frequent dosing and higher doses.
Innovation Solution
Administration of specific polypeptides that bind RANK-L, offering a sustained and prolonged inhibition of bone resorption and osteoclast activity, allowing for less frequent and lower dosing while maintaining effective inhibition, as measured by biomarkers like CTX-1, NTX-1, TRACP5b, PINP, and BAP, with a potency that exceeds preclinical predictions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-size antibodies are used to target RANK-L, then binding affinity and specificity are improved, but production costs increase and accessibility is reduced due to the size and complexity of the molecules
Solution Approach 1:
The patent segments the full-size antibody into smaller functional domains, specifically using single-chain variable fragments (scFv) that contain only the antigen-binding portions of the antibody. This segmentation maintains the essential RANK-L binding capability while eliminating the costly and complex production requirements of full-size antibodies, directly resolving the contradiction between binding reliability and manufacturing ease
Solution Approach 2:
The invention extracts the critical functional elements (variable regions) from the complete antibody structure to create a minimized peptide formulation. By taking out only the necessary antigen-binding domains and removing the Fc region and other non-essential components, the patent achieves both high binding affinity and reduced production complexity
2Reliability
If full-size antibodies are administered, then therapeutic efficacy is improved, but dosing frequency must be high due to rapid clearance and short duration of action
Solution Approach 1:
The patent changes the physical and pharmacokinetic parameters of the therapeutic agent by transitioning from full-size antibodies to smaller peptides. This parameter change in molecular size fundamentally alters the clearance rate and duration of action, allowing for prolonged therapeutic efficacy with less frequent dosing while maintaining the necessary binding affinity for therapeutic effect
3Reliability
If higher doses of RANK-L inhibitors are administered, then inhibition of bone resorption is improved, but side effects and treatment complexity increase
Solution Approach 1:
The patent employs short-lived peptide molecules that are rapidly cleared from the system, allowing for controlled, intermittent dosing regimens. This approach uses smaller, temporary therapeutic agents rather than persistent full-size antibodies, enabling effective bone resorption inhibition through simpler, less frequent dosing schedules that reduce treatment complexity and potential side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides provide unexpectedly prolonged inhibition of RANK-L mediated bone resorption and osteoclast activity, reducing biomarker levels by 30-70% for extended periods, enabling less frequent and lower dosing schedules without compromising efficacy, thus addressing the limitations of existing treatments.
Implementation Method 1
RANK-L, expressed by osteoblasts and bone marrow stromal cells, binds to its functional receptor, RANK, to stimulate differentiation of osteoclasts from precursor cells
Data Source
AI summary
Methods are provided for inhibiting bone resorption and/or osteoclast activity. More specifically, methods are provided wherein polypeptides against RANK-L are administered to a subject less frequently and/or at lower dose, while still maintaining effective inhibition of bone resorption and/or osteoclast activity in the subject at unexpectedly prolonged periods of time, particularly in view of the doses administered.